Hao Xiangyong, Li Zihan, Su Xin, Li Jian, Ye Youbao, Wang Cailiu, Xu Xiao, Song Hao, Song Baoling, Lan Xiang, Luo Tian
Department of General Surgery, Gansu Provincial Hospital, No. 204 Donggang West Road, Chengguan District, Lanzhou 730000, China.
The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, China.
Ther Adv Med Oncol. 2025 Aug 20;17:17588359251363102. doi: 10.1177/17588359251363102. eCollection 2025.
Hepatocellular carcinoma (HCC) is a highly lethal disease that exhibits a rising global incidence, and most HCC patients are at an advanced stage at the time of diagnosis. Although lenvatinib has become the first-line option for HCC and its overall survival is not inferior to sorafenib, not all HCC patients could derive benefits from lenvatinib. Therefore, it was urgent to predict which group of HCC patients could derive benefits from lenvatinib and monitor its therapeutic effectiveness during treatment. This review summarized various biomarkers that could be used for prediction of lenvatinib response, including 7 biomarkers that are applied in clinical practice, 11 biomarkers that are applied in clinical practice, and 6 biomarkers that are under exploratory stage. By conducting this first comprehensive analysis of predictive biomarkers for lenvatinib in HCC patients, this review aims to help doctors to assess the response of lenvatinib treatment more accurately and, thus, develop more effective individualized treatment plans.
肝细胞癌（HCC）是一种致死率很高的疾病，在全球的发病率呈上升趋势，大多数HCC患者在确诊时已处于晚期。尽管乐伐替尼已成为HCC的一线治疗选择，且其总生存期不劣于索拉非尼，但并非所有HCC患者都能从乐伐替尼中获益。因此，迫切需要预测哪类HCC患者能从乐伐替尼中获益，并在治疗期间监测其治疗效果。本综述总结了可用于预测乐伐替尼疗效的各种生物标志物，包括7种应用于临床实践的生物标志物、11种应用于临床实践的生物标志物以及6种尚处于探索阶段的生物标志物。通过对HCC患者中乐伐替尼预测生物标志物进行首次全面分析，本综述旨在帮助医生更准确地评估乐伐替尼治疗的反应，从而制定更有效的个体化治疗方案。
